APEIRON’s APN01 shows clinical benefits for severely ill COVID-19 patients in phase 2 trial

Treatment was safe and well tolerated and no drug-related severe adverse events were observed Significant improvement in mechanical ventilator-free Days and reduction in viral RNA load observed Biomarker development supports APN01’s mode of action against SARS-CoV-2 Investigators and experts recommend further development of APN01 in COVID-19 Press release (EN) | Presseaussendung (DE)
March 12, 2021
View the Post